Herbal preparations and “natural” dietary supplements are frequently used by patients with cardiovascular disease – often in the hope of “gently” influencing blood pressure, lipids or symptoms. However, guidelines from European and American professional societies unanimously emphasize that phytotherapeutics and dietary supplements should not replace established lifestyle and pharmacotherapy. In particular, the 2025 focused ESC/EAS update on dyslipidemia therapy concludes, after reviewing the available evidence, that there is insufficient evidence for any supplement that lowers LDL cholesterol while improving cardiovascular risk with reasonable safety.
Autoren
- Tanja Schliebe
Publikation
- PHYTOTHERAPIE PRAXIS
Related Topics
You May Also Like
- Pediatric Retinoblastoma
The Tumor Microenvironment and Modern Eye-Sparing Therapies
- Adherence and management in asthma and COPD
Better to listen to the pharmacist
- Focus Update 2026
Echocardiography in Cardio-Oncology
- Physical activity with IBD
Sport is not murder, but it doesn’t help either
- White and Black Skin Cancer
Biology and Modern Therapeutic Approaches
- Highlights from the AAD Annual Meeting
Atopic Dermatitis: Interesting News on Drug Candidates in Phase III
- Autoimmune Liver Diseases
Innovative Treatment Approaches for PBC, PSC, and AIH: What’s New?
- Myelofibrosis